Top Japanese Stocks For 2014

LOS ANGELES (MarketWatch) - Japanese stocks chugged higher early Thursday, finding support after a record close for the S&P 500 Index (SPX) and by strengthening in the U.S. dollar versus the yen. The Nikkei Stock Average (JP:NIK) rose 0.5% to 15,888.56, and the broader Topix tacked on 0.6%, with gains also coming after Japanese core machinery orders surpassed expectations. Among exporters, Sharp Corp. (JP:6753) (SHCAF) surged 4.7%, Pioneer Corp. (JP:6773) (PNCOF) picked up 3.1% and Nissan Motor Co. (JP:7201) (NSANY) gained 2.4%. Shares of Tokyo Electric Power Co. (JP:9501) (TKECF) were higher by 2% following government approval of the power firm's turnaround plan.

Top Insurance Companies To Buy For 2015: Central Garden & Pet Company (CENTA)

Central Garden & Pet Company produces and sells various products for the pet, and lawn and garden supplies markets in the United States. The company operates in two segments, Pet, and Lawn and Garden. The Pet segment supplies products for dogs and cats comprising edible bones, edible and non-edible chews, dog and cat food and treats, toys, pet carriers, grooming supplies, and other accessories; and food, cages and habitats, toys, chews, and related accessories for birds, small animals, and specialty pets. It also offers animal and household health, and insect control products; aquariums, furniture and lighting fixtures, pumps, filters, water conditioners, food and supplements, and information and knowledge resources for fish, reptiles, and other aquarium-based pets; and products for horses and livestock. This segment sells its products to independent pet distributors, retail chains, grocery stores, mass merchants, and bookstores under various brand names, which include Ada ms, Aqueon, Avoderm, BioSpot, Farnam, Four Paws, Kaytee, Nylabone, Pinnacle, TFH, Zilla, Altosid, Comfort Zone, Coralife, Interpet, Kent Marine, Oceanic Systems, Pet Select, Pre-Strike, Super Pet, and Zodiac. The Lawn and Garden segment provides grass seeds; wild bird feed, bird feeders, bird houses, and other birding accessories; weed, grass, ant and other herbicide, insecticide, and pesticide products; and decorative outdoor lifestyle and lighting products, such as comprising potteries, trellises and other wood products, and holiday lighting products. This segment sells its products to retail chains, independent garden distributors, grocery stores, nurseries, and garden supply retailers under the AMDRO, GKI/Bethlehem Lighting, Ironite, Pennington, Sevin, Grant�s, Lilly Miller, Matthews Four Seasons, New England Pottery, Norcal Pottery, Over-N-Out, Smart Seed, and The Rebels brand names. The Company was founded in 1955 and is based in Walnut Creek, California.

Advisors' Opinion:

• [By Sean Williams]

  Green paw
  The month of May has been one to forget for shareholders of Central Garden & Pet (NASDAQ: CENT  ) (NASDAQ: CENTA  ) . The maker of pet products as well as seeds and herbicides for lawn care tumbled after it missed Wall Street's earnings estimates for a second straight quarter. The biggest downside pressure came from its lawn care segment, which saw expenses rise as fertilizer margins fell. However, now could be the time to consider jumping on board this interesting pet/lawn care hybrid company, as it has the potential to unlock shareholder value in a number of ways.

Top Japanese Stocks For 2014: Network Exploration Ltd (NET)

Network Exploration Ltd. is an exploration and development-stage company. The Company�� principal business activities include the exploration of minerals in its mineral properties. It focuses on base and precious metal properties in North and South America. Its activities include the process of exploring its mineral properties, reviewing and subsequently acquiring mineral properties and conducting exploration programs to determine whether these properties contain ore reserves that are recoverable. The Picha copper-silver project is located within the Tertiary Volcanic Arc of Southern Peru. The Pistala project is located east of the NW-SE trending Incapquio fault system in the Department of Tacna, Southern Peru. The Company is in the business of mineral exploration in Canada, Chile and Peru. Network Exploration Chile Limitada is its wholly owned subsidiary. Advisors' Opinion:

• [By Holly LaFon]

  MSCI All Country World Index (Net) is an unmanaged index comprised of 44 country indices comprising 23 developed and 21 emerging market country indices and is calculated with dividends reinvested after de duction of withholding tax. The Index is a trademark of Morgan Stanley Capital International and is not available for direct investment.

• [By Jason Rivera]

  Assets:Book Value:Reproduction Value:Current AssetsCash And Cash Equivalents506506Accounts Receivable (Net)3,6193,076Inventories10,0006,000Deferred Income Taxes919460Prepaid Expenses799400Total Current Assets15,8439,986PP&E Net2,4151,449Equity and Other Investments4,5763,432Intangible Assets3,1391,570Deferred Income Taxes991496Total Assets26,96417,387
  Number of shares is 7,383.

• [By Damian Illia]

  Although the company is overly relying on Afrezza, there is to say that MannKind has inked some deals in the recent past. These were primarily aimed to furthering its pipeline development but with less risk and with less research and development expenditure directly for the firm. In November, 2012 it signed a license agreement with Colby Pharmaceutical Company granting the latter exclusive rights to its early stage cancer program. Currently, the firm is also looking for partners regarding Afrezza. Last year in July, it entered one with Deerfield that ensured financing worth $160 million for MannKind. Also, in October 2012, the company raised $86 million (net) through the issuance of shares and has almost $120 million left under its credit facility. This has removed some concerned about a financial crisis in the company, although it hasn't done so throughly.

Top Japanese Stocks For 2014: Clovis Oncology Inc (CLVS)

Clovis Oncology, Inc. (Clovis) incorporated on April 20, 2009, is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor. Effective November 19, 2013, Clovis Oncology Inc acquired the entire share capital of Ethical Oncology Science SpA.

CO-101 - a Lipid-Conjugated Form of the Anti-Cancer Drug Gemcitabine

CO-101 is designed to treat patients with pancreatic cancer whose tumors express low amounts of a membrane transporter protein on the surface of the cancer cell known as hENT1 and are thus expected to be resistant to standard gemcitabine-based therapy. Based on the published results of multiple studies assessing the correlation of hENT1 expression to survival outcomes in pancreatic cancer patients treated with gemcitabine, the Company estimates that approximately 40% to 50% of pancreatic patients express low levels of hENT1, and thus derive little or no benefit from gemcitabine therapy. CO-101 is in an international, randomized and controlled 360-patient study for the first-line treatment of metastatic pancreatic cancer. This open-label study compares CO-101 to gemcitabine as a first-line therapy in patients with metastatic pancreatic cancer. Clovis is partnered with Ventana Medical Systems for the development and commercialization of a companion diagnostic for the assessment of hENT1 levels.

CO-1686-an Oral EGFR Mutant-Selective ! Inhibitor

CO-1686 is an orally available, small molecule covalent inhibitor of the cancer-causing mutant forms of EGFR for the treatment of non-small cell lung cancer (NSCLC). CO-1686 targets both the initial activating EGFR mutations as well as the primary resistance mutation, T790M, it treats both first- and second-line NSCLC patients with EGFR mutations. Such initiating activating mutations occur in approximately 10% to 15% of NSCLC cases in Caucasian patients and approximately 30% to 35% of NSCLC cases in East Asian patients. Following treatment with approved NSCLC therapies, Tarceva (erlotinib) or Iressa (gefitinib), both known as tyrosine kinase inhibitors (TKIs), approximately half of these patients develop the T790M mutation.

The Company focuses on the development of CO-1686 as both a second-line therapy for EGFR-mutated NSCLC patients who become resistant to TKIs due to the emergence of the T790M secondary mutation and as a first-line treatment for EGFR-mutated NSCLC. Clovis is partnered with Roche Molecular Systems for the development and commercialization of a companion diagnostic for identification of EGFR mutations.

CO-338-a PARP Inhibitor

CO-338 is a small molecule PARP inhibitor that the Company focuses to develop as both monotherapy and in combination with chemotherapeutic agents for the treatment of selected cancer patients. CO-338 is in a Phase I clinical trial to determine the maximum tolerated dose of oral CO-338 that can be combined with intravenous, or IV, platinum chemotherapy in the treatment of solid tumors. This program is supplemented by two ongoing investigator-initiated trials, using the IV formulation of CO-338: a Phase I/II study in germ-line BRCA mutant breast and ovarian cancer and a Phase II study in the adjuvant treatment of germ-line BRCA mutant and triple-negative breast cancer. The Company also focuses on initiating a Phase I monotherapy study of the oral formulation, to determine an appropriate dose and schedule.!

The Company competes with Eli Lilly, Teva Pharmaceutical Industries, APP Pharmaceuticals, AB Science SA, Amgen Inc., Astellas Pharma, BioSante Pharmaceuticals, Inc., Celgene Corporation, Immunomedics, Inc., Lorus Therapeutics, Threshold Pharmaceuticals, Inc., Boehringer Ingelheim, Pfizer, Sanofi-Aventis, Astra Zeneca, Abbott, Merck, Eisai, Cephalon and Biomarin.

Advisors' Opinion:

• [By Brian Orelli]

  Plenty of data was presented at the American Society for Clinical Oncology meeting over the weekend, causing the first set of ASCO pops, but Clovis Oncology (NASDAQ: CLVS  ) looks like the clear winner, more than doubling today as the company presented data on its two cancer drugs rucaparib and CO-1686.

Top Japanese Stocks For 2014: Columbia Sportswear Company(COLM)

Columbia Sportswear Company, together with its subsidiaries, engages in the design, development, sourcing, marketing, and distribution of outdoor apparel, footwear, accessories, and equipment in the United States, Latin America, the Asia Pacific, Europe, the Middle East, Africa, and Canada. It provides apparel, accessories, and equipment for men, women, and youth under Columbia and Mountain Hardwear brands used during outdoor activities, such as skiing, snowboarding, hiking, climbing, mountaineering, camping, hunting, fishing, trail running, water sports, and adventure travel. The company also offers footwear products, including lightweight hiking boots, trail running shoes, rugged cold weather boots, sandals, and casual shoes for men and women under Columbia, Sorel, and Montrail brands, as well as for youth under the Columbia and Sorel brands. Columbia Sportswear Company sells its products through wholesale distribution channels, independent distributors, direct-to-consum er channels, and licensees, as well as online to independent distributors and consumers. As of December 31, 2011, it operated 43 outlet retail stores and 8 branded retail stores in the United States; 7 outlet retail stores and 3 branded retail stores in various locations in western Europe; and 2 outlet retail stores in Canada, as well as 111 and 236 dealer-operated, branded, outlet, and shop-in-shop locations in Japan and Korea. Columbia Sportswear Company was founded in 1938 and is headquartered in Portland, Oregon.

Advisors' Opinion:

• [By John Kell]

  Columbia Sportswear Co.'s(COLM) fourth-quarter profit slipped 7% as an asset impairment charge weighed on the active outdoor apparel maker’s bottom line, masking a rise in revenue. Shares rose 6.4% to $83.70 premarket.

Top Japanese Stocks For 2014: First Trust Large Cap Growth AlphaDEX Fund (FTC)

First Trust Large Cap Growth AlphaDEX Fund (the Fund), formerly First Trust Large Cap Growth Opportunities AlphaDEX Fund, is an exchange-traded fund. The investment objective of the Fund is to seek investment results that correspond generally to the price and yield of an equity index called the Defined Large Cap Growth Index (the Index). The Index is an enhanced index created and administered by Standard & Poor��, which employs the AlphaDEX stock selection methodology to select stocks from the S&P 500 Growth Index. Standard & Poor�� constructs the Defined Large Cap Growth Index by ranking the stocks from the S&P 500 Growth Index against all the stocks in the S&P 500 Index on growth factors including 3, 6 and 12-month price appreciation, sales to price and one year sales growth, and separately on value factors, including book value to price, cash flow to price and return on assets. First Trust Advisors L.P. is the adviser of the Fund. Advisors' Opinion:

• [By reports.droy]

  Dollar General�� management still remains optimistic as they have remarked that the ��nti-trust issues��are manageable. Company sources have confirmed that on September 2, the management has sweetened the proposal and send it to the Board of Directors of Family Dollar Stores. Under the terms of the revised proposal, Dollar General is ready to increase the bid to $80 per share in an all-cash deal. To further pacify the Family Dollar top brass, Dollar General�� management has agreed to divest nearly 1500 outlets if ordered by the Federal Trade Commission (FTC), from the 700 store divestiture commitment given during the initial bid.